Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
暂无分享,去创建一个
Daniel Li | Xueyan Chen | M. Wurfel | D. Maloney | C. Turtle | S. Riddell | W. Liles | Junmei Chen | José A López | L. Hanafi | Junmei Chen | Stanley R Riddell | Mark M Wurfel | D. Chung | Cameron J Turtle | Laïla-Aïcha Hanafi | Sindhu Cherian | David G Maloney | Kevin A Hay | Juliane Gust | W Conrad Liles | Dominic Chung | Susanna Harju-Baker | S. Cherian | J. Gust | K. Hay | Daniel H. Li | Susanna Harju-Baker | Xueyan Chen
[1] H. Augustin,et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. , 2004, Blood.
[2] D. Metcalf,et al. Formation and function of Weibel-Palade bodies , 2008, Journal of Cell Science.
[3] K. Kain,et al. Serum Angiopoietin-1 and -2 Levels Discriminate Cerebral Malaria from Uncomplicated Malaria and Predict Clinical Outcome in African Children , 2009, PloS one.
[4] K. Kain,et al. Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[6] Alison Fox-Robichaud,et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis* , 2011, Critical care medicine.
[7] S. Riddell,et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.
[8] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[9] J. Voorberg,et al. Functional architecture of Weibel-Palade bodies. , 2011, Blood.
[10] W. Liles,et al. Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction , 2013, Virulence.
[11] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[12] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[13] K. Kain,et al. Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome. , 2013, The Journal of infectious diseases.
[14] W. Liles,et al. Biomarkers of endothelial activation/dysfunction in infectious diseases , 2013, Virulence.
[15] D. Teachey,et al. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.
[16] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[17] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[18] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[19] M. Wurfel,et al. Biomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness , 2015, PloS one.
[20] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[22] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[23] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[24] S. Heimfeld,et al. CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia , 2016 .
[25] J. Kochenderfer,et al. Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.
[26] Syed Abbas Ali,et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.
[27] D. Teachey,et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. , 2016, Journal of immunological methods.
[28] G. Wertheim,et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.
[29] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[30] D. Teachey,et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia , 2017, Critical care medicine.
[31] C. Turtle,et al. Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies , 2017, Drugs.
[32] S. Riddell,et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.
[33] N. Bartlett,et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.